Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

59 results about "Thienopyridine Derivatives" patented technology

Tetrahydro thienopyridine derivative for treating

The invention provides a novel tetrahydro thienopyridine derivative. The dosage of one or more active compounds in the novel tetrahydro thienopyridine derivative is 0.1-20mg / kg body weight, and the preferable dosage is 0.1-5mg / kg body weight. The novel tetrahydro thienopyridine derivative can be used for producing medicines for preventing and / or treating diseases induced by thrombosis or thromboembolism.
Owner:HC SYNTHETIC PHARMA CO LTD

Process to prepare clopidogrel

The present invention relates to a process for the preparation of thieno[3,2-c]pyridine derivatives having pharmacologically significant anti-aggregating and anti-thrombotic properties.
Owner:CADILA HEALTHCARE LTD

Process to prepare clopidogrel

The present invention relates to a process for the preparation of thieno[3,2-c]pyridine derivatives having pharmacologically significant anti-aggregating and anti-thrombotic properties.
Owner:CADILA HEALTHCARE LTD

Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections

Methods and pharmaceutical compositions for treating viral infections, by administering certain thienopyridine derivative compounds in therapeutically effective amounts are disclosed. Methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment of viral infections such as caused by flavivirus is disclosed, i.e., including but not limited to, Dengue virus, West Nile virus, yellow fever virus, Japanese encephalitis virus, and tick-borne encephalitis virus.
Owner:SIGA TECH INC

Optically active 2-hydroxyltetrahydrothienopyridine derivative as well as preparation method and use thereof

The invention provides an optically active 2-hydroxyltetrahydrothienopyridine derivative shown by formula I, or a pharmaceutically acceptable salt, solvate, polycrystal, enantiomer or racemization mixture thereof, wherein in the formula I, R1 is F, Cl, Br or I; m is 0 or 1; n is an integer from 1 to 6; R2 or R3 is independently hydrogen, C1-C6 alkyl or optionally substituted C1-6 alkyl; R4 or R5 is independently hydrogen, C1-C10 alkyl, C1-C10 alkenyl, C1-10 alkoxy, C1-10 aryl, halogen, acylamino, sulfmidyl, acyloxy or C(O)R', and R' is hydrogen, C1-C10 alkyl, C1-C10 alkenyl, C1-10 alkoxy, C1-10 aryl, halogen, acylamino, sulfmidyl or acyloxy. The compound has obvious platelet agglomeration resistance action, and the bioavailability of the compound is obviously higher than that of clopidogrel. The invention further provides a preparation method of the compound, a pharmaceutical composition containing the compound, and a pharmaceutical use of the compound and the pharmaceutical composition.
Owner:BEIJING PRELUDE PHARM SCI & TECH

Thienopyridine Derivatives

[Problem to be Solved]The present invention provides a compound promoting osteogenesis. [Solution]The present invention provides a compound having the following general formula (I) wherein R1 is H or alkyl, R2 is RaS—, RaO—, RaNH—, Ra(Rb)N— or cyclic amino, and Ra and Rb are alkyl which may be substituted, cycloalkyl which may be substituted, or the like, or a pharmacologically acceptable salt thereof.
Owner:SANKYO CO LTD

Preparation method and medical application of water-soluble 2-hydroxyl tetrahydrothienopyridine derivatives

The invention relates to the field of pharmacy and specifically relates to water-soluble 2-hydroxyl tetrahydrothienopyridine derivatives as well as a preparation method of the derivatives and application of the derivatives in pharmacy, and specifically relates to application of the water-soluble 2-hydroxyl tetrahydrothienopyridine derivatives in preparation of drugs for preventing or treating thrombus and embolism related diseases, and in particular to application of the water-soluble 2-hydroxyl tetrahydrothienopyridine derivatives in prevention and treatment of acute ST segment elevation type myocardial infarction as injections.
Owner:JIANGSU VCARE PHARMATECH

Thienopyridine derivatives, and preparation methods and medical use thereof

ActiveCN103694250AMetabolic avoidanceSolve the problem of resistanceOrganic chemistryBlood disorderClopidogrel resistanceLiver and kidney
The invention belongs to the field of pharmaceutical chemistry technology, and particularly discloses thienopyridine derivatives, and preparation methods and a medical use thereof. Through structural modification of clopidogrel and prasugrel, a series of new thienopyridine derivative compounds are synthesized and mainly include derivatives esterified with ligustrazine formic acid and shikimic acid; the compounds go into a body, then are rapidly metabolized into effective metabolites and ligustrazine formic acid or shikimic acid, successfully keep away from metabolism of CYP2C19 enzyme, can be directly metabolized into active compounds to play a pharmacological function, thereby solving the clopidogrel resistance problem, effectively improving the compound antithrombotic activity, and also having no significant effect on hemorrhage risk; and the compounds have relatively ideal protective function on liver and kidney, and also have potential therapeutic significance for other cardiovascular diseases.
Owner:WUHAN QR PHARMA CO LTD

Thienopyridine derivatives and use thereof as hsp90 modulators

The invention relates to novel thienopyridine derivatives of formula (I), where R<1>, R<2>, R<3> and Y have the meanings given in claim 1, which are HSP90 inhibitors and can be used for the production of a medicament for the treatment of diseases in which the inhibition, regulation and / or modulation of HSP90 play a role.
Owner:MERCK PATENT GMBH

Thienopyridine derivatives, preparation method and application thereof

The invention belongs to the technical field of drugs resisting platelet aggregation, in particular to thienopyridine derivatives with the structure of a formula I and salts thereof, wherein n is equal to 0 and 1; R1 is C1-C4 alkyl; R2 and R3 are simultaneously or respectively hydrogen, C1-C4 alkyl, C1-C4 alkoxy, halogen and halogenated methyl; and R4 is C1-C4 alkyl. The invention also relates to a preparation method of the compounds, and discloses a drug composition with the compounds or salts thereof as active effective components, and application of the compounds in preparing the drugs for resisting the platelet aggregation.
Owner:TIANJIN INSTITUTE OF PHARMA RESEARCH

Deuterated thienopyridine derivative, and preparation method and application thereof

The invention relates to a deuterated thienopyridine derivative, and a preparation method and an application thereof. The deuterated thienopyridine derivative provided by the invention has a structureas shown in a formula (I) which is described in the specification. The invention also comprises an application of the deuterated thienopyridine derivative as a drug used for treatment and preventionof cardiovascular and cerebrovascular diseases.
Owner:JIANGSU TASLY DIYI PHARMA CO LTD

Preparation method of 2-formamido thienopyridine derivatives and medical uses

The invention discloses preparation method of 2-formamido thienopyridine derivatives and uses in preparing antineoplastic medicine compositions, The experiment results show that the 2-formamido thienopyridine derivatives has antitumor action, which can be used as main active components to prepare new antineoplastic medicine and provide new selection for treatment of tumour.
Owner:SICHUAN UNIV

Thienopyridines

The invention relates to novel thienopyridine derivatives of formula (I), wherein R1, R2, R3, R4 and Y have the meaning cited in claim 1, are HSP90-inhibitors and can be used for producing a medicament for treating illnesses, wherein the inhibition, regulation and / or modulation of HSP90 plays a roll.
Owner:MERCK PATENT GMBH

Polysubstituted thieno[2,3-b]pyridine derivatives, and preparation method and application thereof

The invention discloses polysubstituted thieno[2,3-b]pyridine derivatives, and a preparation method and an application thereof. The structural formula of the derivatives are represented by formula I shown in the description. A compound for inhibiting a urea transporter is screened by using an erythrocyte model. Experimental results show that the compounds (represented by formula I-1) can inhibit the permeation of a urea transporter UT-B mediated erythrocyte membrane to urea, and the effect of the compounds has a dose-dependent relationship; the compounds represented by the formula I-1 have nocytotoxic effect on MDCK cells within an effective dose range, so the effect of the compounds represented by the formula I-1 on inhibiting cell permeation urea is irrelevant to the cytotoxicity of thecompounds; the inhibition effect of the compounds represented by the formula I-1 on the urea transporter UT-B is gradually enhanced; the inhibiting effect of the compounds represented by the formulaI-1 on the UT-B is reversible; and in-vivo test results show that the compounds represented by the formula I-1 can significantly increase the urination volume of rats, reduce the concentration of ureain rat urine and reduce the osmotic pressure, so that the compounds represented by the formula I-1 generate a urea selective diuresis effect in vivo.
Owner:PEKING UNIV

Thienopyrimidine and thienopyridine derivatives substituted with cyclic amino group

An object of the present invention is to provide an antagonist against CRF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastral diseases, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alpecia, irritable bowel syndrome, sleep disorders, dermatitides, schizophrenia, pain, etc. A thienopyrimidine or thienopyridine derivative substituted with a cyclic amino group represented by the following formula [I]: has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved.
Owner:TAISHO PHARMACEUTICAL CO LTD

Thienopyridine derivative, and preparation method and application thereof

The invention discloses a thienopyridine derivative with a novel structure, a preparation method thereof and application thereof, and belongs to the field of medicaments. A pharmacological test proves that the thienopyridine derivative shown as a formula 4 has remarkable proliferation inhibition effect on human hepatoma cells HepG2 and the proliferation inhibition effect is achieved by inducing apoptosis; and a new anti-tumor medicament prepared from a 3-amino-thieno[2,3-b]pyridine-2-formamide derivative serving as a main active ingredient is a new choice for the treatment of tumors.
Owner:SICHUAN UNIV

Bi-thienopyridine type derivative and preparation method thereof

The invention discloses a bi-thienopyridine type derivative and a preparation method thereof. The bi-thienopyridine derivative disclosed by the invention adopts a rigid near plane structure, a skeleton structure is the combination of thiophthene and pyridine, a conjugation system is larger, and the double-thienopyridine derivative belongs to the technical field of synthesis. The general formula of a preparation reaction is shown as follows. The coordination compound uses 3, 4-diamino thieno [2, 3-b] thiophene -2, 5- denitrile as a raw material, under the induction of a catalyst, the raw material and ketone or aldehyde generate a Friedlander reaction, and a series of bi-thienopyridine derivatives are synthesized in a one-pot method. The operation process is simple, the atom economy is high, the reaction conditions are mild, and the yield is high. The material of the derivative can be used as a luminescent material, and can be used as the material of a luminous layer in a light emitting device. The synthetic method is one of the manners of magnetic stirring, hydrothermal reactions, microwaves, solid phase synthesis and the like. Through the adoption of the preparation method disclosed by the invention, different substrates can be used for synthesizing various bi-thienopyridine type derivatives which are not reported in literatures.
Owner:BEIJING INSTITUTE OF TECHNOLOGYGY

Thienopyridine derivatives , their production and use

InactiveUS20030130517A1Superior prophylacticSuperior therapeutic efficacyOrganic active ingredientsOrganic chemistryThienopyridine DerivativesTerthiophene
The present invention provides thienopyridine derivatives, which are useful as anti-inflammatory drugs, particularly as remedies for arthritis; processes for producing them, and pharmaceutical compositions containing them. The thienopyridine derivatives are represented by the formula (I): wherein G is a halogen atom, hydroxyl group, an optionally substituted amino group, etc.; alk is an optionally substituted lower alkylene group; X is O, S, -(CH2)q-, etc.; R is an optionally substituted amino group, etc.; ring B is an optionally substituted Y-containing 5- to 8-membered ring whose ring constituent atoms contain no nitrogen atom; Y is O, S, a group of (wherein Ra, Rb and Rc are the same or different and, each is H, a halogen atom, an optionally substituted hydrocarbon group, etc.), etc.; and ring A may be substituted.
Owner:TAKEDA PHARMA CO LTD

Thienopyridine derivatives and their use

There is disclosed a compound of the formula (A):wherein W is C-G or C-G' (G is optionally esterified carboxyl; and G' is halogen); X is oxygen, optionally oxidized sulfur or -(CH2)q-, (q is 0 to 5); R is optionally substituted amino or heterocyclic group; the ring B is optionally substituted nitrogen-containing 5- to 7-membered ring; L is hydrogen, optionally substituted hydrocarbon residue, optionally substituted acyl, optionally substituted carbamoyl, optionally substituted thiocarbamoyl or optionally substituted sulfonyl provided that, when W is C-G, L is hydrogen, optionally substituted acyl, optionally substituted carbamoyl, optionally substituted alkoxycarbonyl, optionally substituted thiocarbamoyl or optionally substituted sulfonyl; n is 0 or 1; the ring A may have a substituent. A process for producing the compound (A) and a pharmaceutical composition containing the compound (A) are also disclosed. The pharmaceutical composition is useful for an anti-inflammatory drug, particularly, a drug for preventing or treating arthritis, a drug for inhibiting bone resorption, immunosuppressant or the like.
Owner:TAKEDA PHARMA CO LTD

Synthetic method of pyrazolo[3,4-b]thieno[2,3-e]pyridine derivative

The invention relates to synthesis of a pyrazolo[3,4-b]thieno[2,3-e]pyridine derivative, in particular to synthesis of pyrazolo[3,4-b]thieno[2,3-e]pyridine. The pyrazolo[3,4-b]thieno[2,3-e]pyridine derivative is generated by taking aromatic aldehyde, 1-phenyl-3-methyl-5-aminopyrazole and 3-oxosulfolane as raw materials in one step under a solvent-free and catalyst-free condition with a three-component one-pot process. According to the method, a synthesis process has a simple and convenient route, conditions are mild, and the total yield is over 78 percent.
Owner:XUZHOU NORMAL UNIVERSITY

Thienopyridine derivative, method for producing same and organic semiconductor device using same

Disclosed is a novel thienopyridine derivative shown by general formula (1) that is useful as an organic semiconductor device and specifically as an organic thin film transistor. Also disclosed is a method for producing the same. [In the formula, R<1> is a hydrogen atom, optionally substituted alkyl group, optionally substituted alkenyl group, optionally substituted alkynyl group, optionally substituted alkoxy group, optionally substituted aryl group, optionally substituted heteroaromatic ring group, optionally substituted alkylthio group, optionally substituted arylthio group, optionally substituted ester group or a substituent shown by -SO2R<2> (wherein R<2> is an optionally substituted C1-20 hydrocarbon group), and W is at least one substituent selected from a group comprising optionally substituted aryl groups and optionally substituted heteroaromatic ring groups.]
Owner:HIROSHIMA UNIVERSITY +1
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products